

## References

### I-20

1. Preferred Drug List (PDL) Prior Authorization Criteria. North Dakota Department of Human Services. Medical Services Division. <http://www.hidesigns.com/ndmedicaid/pdl/2021.html>
2. Synagis® (palivizumab) [package insert]. Gaithersburg, MD, MedImmune, LLC. 07/2010.
3. Paes BA, Mitchell A, Banerji A, et al. A decade of respiratory syncytial virus epidemiology and prophylaxis: Translating evidence into everyday clinical practice. *Can Respir J*. 2011; 18(2).
4. American Academy of Pediatrics (AAP). Updated guidance for Palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. 2014;415-420. Reaffirmed February 2019.
5. Chu, H. Clinical outcomes in outpatient respiratory syncytial virus infection in immunocompromised children. *Influenza and Other Respiratory Viruses*. 2016;205-210.
6. Ozyurt, A. Efficacy of Palivizumab Prophylaxis Among Infants With Congenital Heart Disease: A Case Control Study. *Pediatric Pulmonology*. 2015; 50:1025-1032.
7. Zembles, T. Implementation of American Academy of Pediatrics guidelines for palivizumab prophylaxis in a pediatric hospital. *Am J Health-Syst Pharm*. 2016;73(6): 405-408.
8. Falloon J, Ji F, Curtis C, et al. A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant. *Vaccine*. 2016;34(25):2847-2854.
9. Glenn GM, Fries LF, Thomas DN, et al. A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. *J Infect Dis*. Feb 1 2016;213(3):411-422.
10. Groves HE, Jenkins L, Macfarlane M, et al. Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland. *Pediatr Pulmonol*. 2016;51(4):379-385.
11. Munoz FM RS, Meissner HC. RSV Recommendations Unchanged after Review of New Data. *AAP News* 2017;<http://www.aappublications.org/news/2017/10/19/RSV101917>.

12. Viguriaa N, Navascués A, Juanbeltz R, Echeverría A, Ezpeleta C, & Castilla J. Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children. *Human Vaccines & Immunotherapeutics*. 2021;17(6):1867-1872.
13. American Academy of Pediatrics. Interim guidance for use of palivizumab prophylaxis to prevent hospitalization from severe respiratory syncytial virus infection during the current atypical interseasonal RSV spread. <https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/interim-guidance-for-use-of-palivizumabprophylaxis-to-prevent-hospitalization/>